Biogen (BIIB.US) stock has been halted after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.
Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5
US OPEN: Capital is once again fleeing “memory stocks”; Wall Street under pressure at the open 🚨
Which earnings reports will be in the spotlight this week❓ (13.07.2026)
Market Wrap: Geopolitical déjà vu. Hormuz once again in the center of investors' attention.
TSMC Shows That Companies Are Still Investing Billions in AI